#wvcusa Marc LaForce discussing now early impact results after the introduction of a new Group A meningococcal conjugate #vaccine in Africa

In Prophylactic Vaccines by Marcia ArdilaLeave a Comment

marc LaForce world vaccine congress
Meningococcal vaccine: Today at World Vaccine Congress Washington, Dr Marc LaForce, Director, Meningitis Vaccine Project, PATH delivered a great presentation about the Impact data on vaccine mass-introduction to Sub-Saharan countries.

Some Key points raised in the presentation:

Overview of epidemic meningitis in Africa: Major epidemics of meningitis occur in the ‘meningitis belt' of sub-Saharan Africa and one strain is responsible for over 80% of cases. Major epidemics occur every 7-14 years.

This lead to WHO recommendation in 2001 for conjugate meningitis vaccines to be developed for Africa; MVP was created in 2001 as a partnership between WHO and PATH. The vaccine is called MenAfriVac and is now fully licensed. This vaccine is far more immunogenic than polysaccharide vaccine in all age groups. Vaccine is made from group A polysaccharide linked to tetanus toxoid.

WHO prequalified the vaccine in June 2010 and immunization was officially launched in December, 2010 in Burkina Faso in 1-29 years of age (75% of population of Burkina Faso). In this immunization campaign, 10.8 millions were immunized in 10 days. A drop in new cases from 6732 in 2010 to 3875 in 2011, or 24.9% of Men A in 2010 to 0.4% in 2011.

Check back here in a couple of days for the presentation. Excellent presentation Marc

Leave a Comment

Current ye@r *